Cargando…
Psychofarmacological approach for Binge- eating disorders
INTRODUCTION: Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) OBJECTIVES: The a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565754/ http://dx.doi.org/10.1192/j.eurpsy.2022.596 |
_version_ | 1784808968092123136 |
---|---|
author | Muñoz Martinez, V. Beato-Fernández, L. Segura-Escobar, E. |
author_facet | Muñoz Martinez, V. Beato-Fernández, L. Segura-Escobar, E. |
author_sort | Muñoz Martinez, V. |
collection | PubMed |
description | INTRODUCTION: Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) OBJECTIVES: The aim of this study was to examine the efficacy of lisdexamfetamine dimesylate in a simple of 50 women with a binge eating disorder diagnosis compare with selective serotonin reuptake inhibitor METHODS: Two groups were made, one with lisdexamfetamine and the other with selective serotonin reuptake inhibitor (fluoxetine). 20 women were in each group (total n=40). The doses depend of the binge symptoms and rates were from 30 to 70md/day for lisdexamfetamine and for fluoxetine the doses were from 20 to 60mg/day. RESULTS: Binge behaviors decreased with a 50mg/day dose of lisdexamfetamine. The 70mg/day doses present also less binge behaviors but also more adverse events. The 30mg/day doses did not decrease binge-eating behaviors. CONCLUSIONS: Lisdexamfetamine is the first pharmacological agent to receive FDA approval for use in adults with moderate to severe binge eating disorder. This study supports further assessment of lisdexamfetamine as a treatment option for decreasing binge eating behavior and also symptoms associated such as anxiety and obsessive and compulsive features in adults.Increased efficacy with increasing dosages of lisdexamfetamine suggests a dose-response relationship until 50mg/day. Women with a dose of 50mg/day of lisdexamfetamine report less adverse event, more adherence to treatment and improve their eating behaviors. DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9565754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95657542022-10-17 Psychofarmacological approach for Binge- eating disorders Muñoz Martinez, V. Beato-Fernández, L. Segura-Escobar, E. Eur Psychiatry Abstract INTRODUCTION: Binge-eating disorder (BED), is one of the most common eating disorder. Treatment aims to reduce binge-eating frequency and disordered eating–related cognitions, improve metabolic health and weight, and regulate mood (in patients with coexisting depression or anxiety) OBJECTIVES: The aim of this study was to examine the efficacy of lisdexamfetamine dimesylate in a simple of 50 women with a binge eating disorder diagnosis compare with selective serotonin reuptake inhibitor METHODS: Two groups were made, one with lisdexamfetamine and the other with selective serotonin reuptake inhibitor (fluoxetine). 20 women were in each group (total n=40). The doses depend of the binge symptoms and rates were from 30 to 70md/day for lisdexamfetamine and for fluoxetine the doses were from 20 to 60mg/day. RESULTS: Binge behaviors decreased with a 50mg/day dose of lisdexamfetamine. The 70mg/day doses present also less binge behaviors but also more adverse events. The 30mg/day doses did not decrease binge-eating behaviors. CONCLUSIONS: Lisdexamfetamine is the first pharmacological agent to receive FDA approval for use in adults with moderate to severe binge eating disorder. This study supports further assessment of lisdexamfetamine as a treatment option for decreasing binge eating behavior and also symptoms associated such as anxiety and obsessive and compulsive features in adults.Increased efficacy with increasing dosages of lisdexamfetamine suggests a dose-response relationship until 50mg/day. Women with a dose of 50mg/day of lisdexamfetamine report less adverse event, more adherence to treatment and improve their eating behaviors. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9565754/ http://dx.doi.org/10.1192/j.eurpsy.2022.596 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Muñoz Martinez, V. Beato-Fernández, L. Segura-Escobar, E. Psychofarmacological approach for Binge- eating disorders |
title | Psychofarmacological approach for Binge- eating disorders |
title_full | Psychofarmacological approach for Binge- eating disorders |
title_fullStr | Psychofarmacological approach for Binge- eating disorders |
title_full_unstemmed | Psychofarmacological approach for Binge- eating disorders |
title_short | Psychofarmacological approach for Binge- eating disorders |
title_sort | psychofarmacological approach for binge- eating disorders |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565754/ http://dx.doi.org/10.1192/j.eurpsy.2022.596 |
work_keys_str_mv | AT munozmartinezv psychofarmacologicalapproachforbingeeatingdisorders AT beatofernandezl psychofarmacologicalapproachforbingeeatingdisorders AT seguraescobare psychofarmacologicalapproachforbingeeatingdisorders |